Recuro Health Closes $47 Million Series B Financing Led by ARCH Venture Partners, Advancing Innovative Virtual-First Care Service

Recuro Health (Recuro), an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused model to a proactive care approach, today announces the closing of a $47 million Series B round investment.

The Series B syndicate includes both new and existing investors, including ARCH Venture Partners, the Flippen Group, GPG Ventures, 4D Capital and other investors.
Recuro Health will use the proceeds to advance and scale its Digital Medical Home, which includes diagnostic-enabled Virtual Primary Care and Virtual Behavioral Health Solutions that are tailored to fit the healthcare needs of any population. The Digital Medical Home care model integrates advanced science, data, at-home diagnostics and targeted genomics — cancer screening, pharmacogenomics – to better inform integrated care.

“The continued support of our investors is a clear sign of their confidence in our mission,” says Michael Gorton, CEO and founder, Recuro Health. “We have an extraordinary team at Recuro dedicated to evolving healthcare to be more proactive and personal, resulting in improved outcomes, better patient engagement and lower costs. In this next phase of our Company growth and expansion, we are committed to building upon the success of our Digital Medical Home and continuing to advance the next generation of digital care services.”

Recuro’s digital health solutions are currently available nationwide and used by millions of members.

Robert Nelsen, co-founder and managing director, ARCH Venture Partners, says, “Recuro is proving to be the best of breed in the intersection of science, diagnostics and digital health. This nimble organization has the ability to quickly respond to market changes, scale its tech-enabled services and close gaps in care that improve population health. We see significant opportunities for exceptional growth and continued success.”

Founded in 2021, Recuro Health has garnered industry recognition as a pioneer in developing innovative digital solutions that integrate Virtual Primary Care and Urgent Care, Behavioral Health, at-home lab testing, genomics as well as a suite of enabling capabilities such as care navigation, data analytics, quality and guided referrals.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”